Cannabinoids and neuroprotection

Molecular Neurobiology

Volumn 24, Issue 1-3, 2001, Pages 29-51

  Grundy, Robert I ^a   Rabuffetti, Monica ^a   Beltramo, Massimiliano ^a  

^a San Raffaele Science Park   (Italy)

Author keywords

Brain trauma; Cannabinoid receptor; Cerebral ischemia; Multiple sclerosis; Neuroprotection; Signaling pathways

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; GLUTAMIC ACID;

ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; RECEPTOR POTENTIAL; SIGNAL TRANSDUCTION;

EID: 0035690887     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (194)

1. Marihuana
2. Isolation, structure and partial synthesis of an active constituent of hashish
3. Determination and characterization of a cannabinoid receptor in rat brain
4. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
5. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
6. Molecular characterization of a peripheral receptor for cannabinoids
7. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
8. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
9. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
10. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
11. A second endogenous cannabinoid that modulates long-term potentiation
12. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP
13. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain
14. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
15. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
16. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion
17. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
18. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization
19. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
20. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor
21. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)
22. Structure activity relationship of tetrahydrocannabinol analogues on human cannabinoid receptors
23. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630
24. HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor
25. Cannabimimetic fatty acid derivatives in cancer and inflammation
26. Cardiovascular effects of endocannabinoids - The plot thickens
27. The endocannabinoid system as a target for therapeutic drugs
28. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development
29. Cannabinoid receptors and pain
30. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
31. Localization of cannabinoid receptor mRNA in rat brain
32. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
33. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
34. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain
35. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
36. Cannabinoid receptor localization in brain
37. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons
38. Distribution of cannabinoid receptor messenger RNA in the human brain: An in situ hybridization histochemistry with oligonucleotides
39. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles
40. 3H] 11-OH-delta 9-THC-DMH
41. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
42. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB
43. Localization of the CB(1) cannabinoid receptor in the rat brain. An immunohistochemical study
44. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves
45. Bidirectional control of airway responsiveness by endogenous cannabinoids
46. Molecular cloning of a human cannabinoid receptor which is also expressed in testis
47. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: Is 2-arachidonoylglycerol a possible vasomodulator?
48. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum
49. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs
50. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
51. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor
52. Signal transduction of eicosanoid CB1 receptor ligands
53. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor
54. Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
55. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons
56. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions
57. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes
58. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
59. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase
60. Functional CB1 cannabinoid receptors in human vascular endothelial cells
61. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes
62. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt
63. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells
64. Regulation of a neuronal form of focal adhesion kinase by anandamide
65. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]
66. The CB1 cannabinoid receptor can sequester G-Proteins, making them unavailable to couple to other receptors
67. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies
68. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells
69. 2+ channels in a neuronal expression system
70. 2+ channel current
71. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system
72. Cannabinoids modulate potassium current in cultured hippocampal neurons
73. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process
74. Protein kinase-dependent phosphorylation and cannabinoid receptor modulation of potassium A current (IA) in cultured rat hippocampal neurons
75. Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons
76. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum
77. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons
78. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro
79. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations
80. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus
81. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells
82. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells
83. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes
84. Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity
85. Tetrahydrocannabinol inhibition of macrophage nitric oxide production
86. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum
87. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
88. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats
89. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
90. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice
91. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
92. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors
93. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
94. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: Implications for antinociception
95. The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling
96. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2
97. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation
98. Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system
99. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression
100. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid
101. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation
102. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells
103. Cannabinoid receptors and immunity
104. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound
105. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease
106. Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: Functional and biochemical parameters
107. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors
108. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor
109. Delta 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: Suppression of post-translational events
110. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice
111. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
112. Delta9-tetrahydrocannabinol enhances the secretion of interleukin-1 from endotoxin-stimulated macrophages
113. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila
114. The role of macrophages in THC-induced alteration of the cytokine network
115. Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60
116. Interleukin-8, a chemotactic and inflammatory cytokine
117. Purification of a monocyte chemotactic factor secreted by non human primate vascular cells in culture
118. In vivo and in vitro treatment with the synthetic cannabinoid CP55940 decreases the in vitro migration of macrophages in the rat: Involvement of both CB1 and CB2 receptors
119. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor
120. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity
121. Non-psychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker
122. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain
123. 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211
124. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
125. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission
126. Interactions between synthetic vanilloids and the endogenous cannabinoid system
127. Anandamide transport inhibition by the vanilloid agonist olvanil
128. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
129. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
130. Anandamide: An endogenous activator of the vanilloid
131. Anandamide and the question of its functional role for activation of capsaicin receptors
132. Are cannabinoids endogenous ligands for the VR1 capsaicin receptor?
133. Anandamide: The other side of the coin
134. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptor
135. Anandamide inhibit binding to the muscarinic acetylcholine receptor
136. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor
137. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes
138. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes
139. Ultrastructural localisation of the CB1 cannabinoid receptor in μ-opiod receptor patches of the rat caudate putamen necleus
140. Calcium tsunamis: Do astrocytes transmit cell death messages via gap junctions during ischemia?
141. Gap-junction-mediated propagation and amplification of cell injury
142. Regulation of astrocyte gap junctions by hypoxia-reoxygenation
143. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death
144. Reactive oxygen involvement in neurodegenerative pathways
145. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants
146. Long-chain N-acylethanolamines inhibit lipid peroxidation in rat liver mitochondria under acute hypoxic hypoxia
147. Control of pain initiation by endogenous cannabinoids
148. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency
149. The role of excitotoxicity in neurodegenerative disease: Implications for therapy
150. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons
151. Cannabinoids inhibit exacitatory neurotransmission in the substantia nigra pars reticulata
152. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro
153. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
154. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices
155. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
156. Activation of CB1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures
157. CB1 Cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum
158. HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture
159. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
160. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures
161. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats
162. Anti-ischemia activity of HU-211, a non-psychotropic synthetic cannabinoid
163. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils
164. HU-211, a non-psychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats
165. HU-211, a novel non-competitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat
166. Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: A quantitative study
167. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia
168. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat
169. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors
170. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
171. A non-psychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat
172. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant
173. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers
174. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway
175. The role of costimulation in autoimmune demyelination
176. Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis
177. Suppression of experimental autoimmune encephalomyelitis by cannabinoids
178. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: Implications for the treatment of acute relapses of multiple sclerosis
179. Cannabinoids control spasticity and tremor in a multiple sclerosis model
180. Endocannabinoids control spasticity in a multiple sclerosis model
181. Treatment of human spasticity with delta 9-tetrahydrocannabinol
182. Tetrahydrocannabinol for tremor in multiple sclerosis
183. Nabilone in the treatment of multiple sclerosis
184. The perceived effects of smoked cannabis on patients with multiple sclerosis
185. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids
186. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study
187. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats
188. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen
189. Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
190. Marijuana for Parkinsonian tremor
191. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol
192. Anandamide induces apoptosis of PC-12 cells: Involvement of superoxide and caspase-3